biostudies-literatureUnknown7(2)Reinmuth N<h4>Introduction</h4>In the phase 3 EVOKE-01 trial (NCT05089734), sacituzumab govitecan (SG) exhibited a numerical improvement in overall survival and tolerability compared with docetaxel in patients with metastatic NSCLC previously treated with platinum-based chemotherapy and programmed cell death protein (ligand) 1 inhibitors, although results were not statistically significant. This analysis evaluated health-related quality of life (HRQoL) data from EVOKE-01.<h4>Methods</h4>Patients (N = 603) were randomized 1:1 to SG (n = 299) or docetaxel (n = 304) in 21-day cycles. HRQoL was assessed by the NSCLC Symptom Assessment Questionnaire (NSCLC-SAQ), European Organization for Research and Treatment of Cancer Quality of Life questionnaire-Core 30 (QLQ-C30), and EuroQol 5 Dimension 3-level quesJTO clinical and research reports100929https://www.ebi.ac.uk/biostudies/studies/S-EPMC12828819biostudies-literaturePatient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial.PMC12828819Couraud SZhang EBaijal SPaz-Ares LGarassino MCFelip EGuo SKato TParra HSRadford MPelligra CGReinmuth NGarrido PMekan SDaniel DPercent IRittmeyer APatel MfalsePatient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial.<h4>Introduction</h4>In the phase 3 EVOKE-01 trial (NCT05089734), sacituzumab govitecan (SG) exhibited a numerical improvement in overall survival and tolerability compared with docetaxel in patients with metastatic NSCLC previously treated with platinum-based chemotherapy and programmed cell death protein (ligand) 1 inhibitors, although results were not statistically significant. This analysis evaluated health-related quality of life (HRQoL) data from EVOKE-01.<h4>Methods</h4>Patients (N = 603) were randomized 1:1 to SG (n = 299) or docetaxel (n = 304) in 21-day cycles. HRQoL was assessed by the NSCLC Symptom Assessment Questionnaire (NSCLC-SAQ), European Organization for Research and Treatment of Cancer Quality of Life questionnaire-Core 30 (QLQ-C30), and EuroQol 5 Dimension 3-level ques2026-01-01T00:00:00Z2026 Feb2026-06-06T22:36:44.751Z2026-06-06T03:10:47.726ZS-EPMC128288194158471810.1016/j.jtocrr.2025.100929